Business
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in ...
About this update from Medicure Inc.
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2026 and will have a conference call to present the Financial Results on May 25, 2026 at 8:30 am Eastern Time. Quarter Ended March 31, 2026 Highlights: Financial Results Net AGGRASTAT® product sales for the three month period ended March 31, 2026, were $979,000 compared to $1.7 million during the period ended March 31, 2025. The decrease in AGGRASTAT® revenues compared to the same period in the prior year is the result of a decrease in the volume of AGGRASTAT® sold and pricing competition from generic tirofiban. Marley Drug recorded net revenue of $3.2 million during the period ended March 31, 2026 compared to net revenue of $3.1 million during the period ended March 31, 2025. The pharmacy business continues to focus on diversifying its revenue by securing exclusive product offerings and partnerships, which helped contribute to the increase in revenue during the current period. Going forward, the focus of Marley Drug is to continue growing its sales of ZYPITAMAG® and increasing its exclusive product offerings and business partnerships. On March 11, 2025, Medicure acquired Gateway Pharmacy, an independent retail pharmacy located in Portland, Oregon. Gateway Pharmacy recorded net revenue of $753,000 during the period ended March 31, 2026, in comparison to net revenue of $175,000 during the period ended March 31, 2025. Given the pharmacy was acquired on March 11, 2025, the revenue recorded during the prior period was only related to product sales between March 11, 2025 to March 31, 2025. On June 16, 2025, the Company acquired West Olympia Pharmacy, an independent retail pharmacy with a substantial customer base, located in Olympia Washington. During the period ended March 31, 2026, West Olympia Pharmacy contributed net revenue of $1.7 million. Given West Olympia Pharmacy was acquired subsequent to March 31, 2025, the Company did not record any net revenue from the pharmacy during the prior period. ZYPITAMAG through insured channels contributed $1.3 million of revenue for the period ended March 3...